{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-049437","form_type":"8-K","ticker":null,"cik":"0001832168","company_name":"Longboard Pharmaceuticals, Inc.","filed_at":"2023-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.573909+00:00","generated_at":"2026-06-10T09:51:05.348351+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Longboard Pharmaceuticals amends bylaws to adopt Universal Proxy Rules and DGCL updates","bullets":["Board approved amended bylaws effective Sept 21, 2023 to address SEC Universal Proxy Rule 14a-19.","New rules require nominating stockholders to disclose proxy solicitation intent and provide compliance evidence.","Clarifies number of nominees cannot exceed directors to be elected; requires non-white proxy card for dissidents.","Updates include adjournment procedures, delivery of notices, and other administrative changes per DGCL."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-049437","json":"https://secwatch.observer/filing/0000950170-23-049437.json","markdown":"https://secwatch.observer/filing/0000950170-23-049437.md","text":"https://secwatch.observer/filing/0000950170-23-049437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832168/000095017023049437/0000950170-23-049437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832168/000095017023049437/lbph-20230921.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T09:51:05.348351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ca971d7c1851cdfe85b4adacf1273edf231daeaf","claim":"Longboard Pharmaceuticals, Inc.: Amended and restated bylaws to address universal proxy rules and make other updates (effective 2023-09-21).","evidence_excerpt":"On September 21, 2023, the Board of Directors (the \"Board\") of Longboard Pharmaceuticals, Inc. (the \"Company\") approved and adopted an amendment and restatement of the Company's bylaws (as amended and restated, the \"Bylaws\"), effective as of the date of such approval.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832168/000095017023049437/0000950170-23-049437-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-09-21"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}